Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

While CD4 T cells are a prerequisite for CD8 T cell-mediated protection against intracellular hepatotropic pathogens, the mechanisms facilitating the transfer of CD4-help to intrahepatic CD8 T cells are unknown. Here, we developed an experimental system to investigate cognate CD4 and CD8 T cell responses to a model-antigen expressed de novo in hepatocytes and reveal that after initial priming, effector CD4 and CD8 T cells migrate into portal tracts and peri-central vein regions of the liver where they cluster with type-1 conventional dendritic cells. These dendritic cells are locally licensed by CD4 T cells and expand the number of CD8 T cells in situ, resulting in larger effector and memory CD8 T cell pools. These findings reveal that CD4 T cells promote intrahepatic immunity by amplifying the CD8 T cell response via peripheral licensing of hepatic type-1 conventional dendritic cells and identify intrahepatic perivascular compartments specialized in facilitating effector T cell-dendritic cell interactions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10858872PMC
http://dx.doi.org/10.1038/s41467-024-45612-5DOI Listing

Publication Analysis

Top Keywords

dendritic cells
16
cd4 cells
12
cd8 cells
12
cd8 cell
12
cells
10
cd4 cd8
8
type-1 conventional
8
conventional dendritic
8
cd8
7
cd4
6

Similar Publications

Chimeric antigen receptor (CAR) therapies have demonstrated remarkable clinical efficacy in hematological malignancies, validating their therapeutic potential. However, challenges such as therapeutic resistance and limited accessibility hinder their broader application. To overcome these limitations, alternative CAR-based cell therapies, including CAR-Natural Killer (CAR-NK), CAR-macrophage (CAR-M), and CAR-dendritic cell (CAR-DC) therapies, have been proposed.

View Article and Find Full Text PDF

IL12-based phototherapeutic nanoparticles through remodeling tumor-associated macrophages combined with immunogenic tumor cell death for synergistic cancer immunotherapy.

Biomater Sci

September 2025

Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, The Tianjin Key Laboratory of Biomaterials, Institute of Biomedical Engineering, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin, 300192, China.

Various cancer therapeutic strategies have been designed for targeting tumor-associated macrophages (TAMs), but TAM reprogramming-based monotherapy is often clinically hindered, likely due to the lack of a coordinated platform to initiate T cell-mediated immunity. Herein, we fabricated reactive oxygen species (ROS)-responsive human serum albumin (HSA)-based nanoparticles (PEG/IL12-IA NPs) consisting of indocyanine green (ICG), arginine (Arg), and interleukin 12 (IL12). Upon laser irradiation, the nanoparticles were found to be able to dissociate, thus facilitating the release of IL12.

View Article and Find Full Text PDF

The effect of CD40 agonist antibody therapy on the pancreatic cancer microenvironment.

Naunyn Schmiedebergs Arch Pharmacol

September 2025

Department of Gastroenterology, Jinhua Central Hospital, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, Zhejiang, China.

The fourth leading cause of cancer-related fatalities in the USA is pancreatic ductal adenocarcinoma (PDAC), a particularly deadly illness that is resistant to immunotherapy. One of the Main Obstacles in cancer research is developing better treatments for PDAC, which has the lowest 5-year survival rate of any malignancy. Anti-CTLA-4, anti-PD-L1, and anti-PD-1 immune checkpoint blockade medications also have poor results in these patients, which may indicate the presence of other immunosuppressive mechanisms in the pancreatic tumor microenvironment (TME).

View Article and Find Full Text PDF

Purpose: To characterize corneal immune cell morphodynamics and nerve features, and define the in vivo immune landscape in older adults with human immunodeficiency virus (HIV) receiving antiretroviral therapy (ART), relative to healthy age-matched adults.

Methods: In this cross-sectional study, 16 HIV-positive individuals receiving ART and 15 age-matched controls underwent ocular surface examinations and functional in vivo confocal microscopy (Fun-IVCM). Time-lapsed videos were created to analyze corneal immune cells (T cells, dendritic cells [DCs], macrophages).

View Article and Find Full Text PDF

Background: Vaccination is a key strategy to reduce infectious disease mortality. In pediatric heart transplant recipients (HTRs), the use of immunosuppressive therapy weakens immune responses, increasing the risk of viral infections. This study aimed to evaluate the immunogenicity of hepatitis B virus (HBV) revaccination in this vulnerable population.

View Article and Find Full Text PDF